Molecular investigation of ALK‐rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion‐independent transcription activation. Issue 8 (29th March 2022)

• Record Type: Journal Article
• Authors: Georgantzoglou, Natalia; Green, Donald; Winnick, Kimberly N.; Sumegi, Janos; Charville, Gregory W.; Bridge, Julia A.; Linos, Konstantinos
• Is Part Of: Genes, chromosomes & cancer. Volume 61:Issue 8(2022)
• Page Start: 471
• Page End: 480
• Publication Date: 2022-03-29
• Subjects: ALK -- CLTC -- epithelioid fibrous histiocytoma -- fusion partner -- NGS; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.23038
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Epithelioid fibrous histiocytoma (EFH) is a rare cutaneous neoplasm, which is characterized by the presence of rearrangements involving the ALK gene. Although EFH was long considered a variant of fibrous histiocytoma, the identification of its unique genetic signature confirmed that it represents a distinct entity. The aim of the present study was to examine a cohort of ALK‐immunoreactive EFH cases to further characterize gene fusion partners. Next generation sequencing detected ALK fusions in 11 EFH cases identified in the pathology archives of two different institutions. The most common fusion partner was DCTN1 ( N = 4) followed by CLTC ( N = 2) and VCL ( N = 2), while the remaining cases harbored fusions involving SPECC1L, PPFIBP1, and PRKAR1A . In one case no fusion was detected by NGS and FISH despite suitable sample quality. Notably, IHC demonstrated positive ALK expression and the level of aligned ALK reads was comparable to the fusion‐positive cases. To the best of our knowledge, this is the first report of CLTC as a fusion partner in EFH. The two CLTC rearranged cases in our cohort also represent the first two EFH cases in the literature that involve exon 19 of ALK, instead of exon 20. These findings underscore the remarkable plasticity of ALK as an oncogenic driver and further expand the list of its potential fusion partners in EFH. Lastly this is also the first report of ALK‐immunoreactive EFH with no underlying fusion suggesting a fusion independent transcription mechanism as seen in other tumors.